title: Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience.
abstract: OBJECTIVE
  To evaluate the location, histopathology, stages, and treatment of gastric cancer and to conduct survival analysis on prognostic factors.
  
  
  METHODS
  Patients diagnosed with of stomach cancer in our clinic between 2000 and 2011, with follow-up or a treatment decision, were evaluated retrospectively. They were followed up by no treatment, adjuvant therapy, or metastatic therapy. We excluded from the study any patients whose laboratory records lacked the operating parameters. The type of surgery in patients diagnosed with gastric cancer was total gastrectomy, subtotal gastrectomy or palliative surgery. Patients with indications for adjuvant treatment were treated with adjuvant and/or radio-chemotherapy. Prognostic evaluation was made based on the parameters of the patient, tumor and treatment.
  
  
  RESULTS
  In this study, outpatient clinic records of patients with gastric cancer diagnosis were analyzed retrospectively. A total of 796 patients were evaluated (552 male, 244 female). The median age was 58 years (22-90 years). The median follow-up period was 12 mo (1-276 mo), and median survival time was 12 mo (11.5-12.4 mo). Increased T stage and N stage resulted in a decrease in survival. Other prognostic factors related to the disease were positive surgical margins, lymphovascular invasion, perineural invasion, cardio-esophageal settlement, and the levels of tumor markers in metastatic disease. No prognostic significance of the patient's age, sex or tumor histopathology was detected.
  
  
  CONCLUSIONS
  The prognostic factors identified in all groups and the proposed treatments according to stage should be applied, and innovations in the new targeted therapies should be followed.
authors.affiliation: Medical Oncology, Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa, 34300 Istanbul, Turkey. fsbiricik@yahoo.com
authors.forename: Fatih
authors.initials: F
authors.lastname: Selcukbiricik
authors.forename: Evin
authors.initials: E
authors.lastname: Buyukunal
authors.forename: Deniz
authors.initials: D
authors.lastname: Tural
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ozguroglu
authors.forename: Fuat
authors.initials: F
authors.lastname: Demirelli
authors.forename: Suheyla
authors.initials: S
authors.lastname: Serdengecti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D055815:Young Adult
keywords: Chemotherapy; Gastric carcinoma; New agents; Prognostic factors; Survival; Treatment